Abvc Biopharma, INC

ABVC BioPharma has postponed its previously announced distribution of BioKey (Cayman), Inc. ordinary shares from August 3, 2026, to August 21, 2026, to finalize administrative, regulatory, and tax matters.

ABVC BioPharma, Inc. has dismissed Simon & Edward, LLP and engaged Kreit & Chiu CPA LLP as its new independent registered public accounting firm.

ABVC BioPharma, Inc. shareholders re-elected all 11 directors, ratified the auditor, and approved an increase to the equity incentive plan at their 2026 annual meeting.

ABVC BioPharma, Inc. filed an amendment detailing additional unregistered sales of 1.5 million common shares, raising $2.28 million, with purchasers transferring voting rights to the chairman.

ABVC BioPharma announced strong Q3 2025 financial results, including a 230% year-over-year increase in licensing revenue and significant asset expansion.

ABVC BioPharma's Board approved a new performance incentive plan for directors and officers, contingent on achieving a $1 billion market cap by December 2027.

ABVC BioPharma reported continued net losses and a working capital deficit in its Q2 2026 filing, raising substantial doubt about its going concern status.

ABVC BioPharma, Inc. reported a net loss of $1.69 million for the first quarter of 2026, a significant increase from the prior year's loss, with no revenue generated.

ABVC BioPharma posted an increased net loss in Q3 2025, driven by higher operating expenses, despite revenue growth and significant asset expansion through land acquisitions and debt reduction.

ABVC BioPharma reported a reduced net loss for the six months ended June 30, 2025, despite zero revenue, while addressing prior financial restatements and ongoing liquidity concerns.

ABVC BioPharma reports a net loss for Q1 2025 and discusses efforts to improve its financial position, including addressing a Nasdaq compliance issue and managing convertible debt.

ABVC BioPharma saw a significant increase in revenue and a substantial reduction in net loss for the third quarter of 2024, driven by licensing agreements and cost controls.

ABVC BioPharma, Inc. reported a significant increase in net loss and no revenue for the fiscal year ended December 31, 2025, alongside ongoing clinical trial progress and efforts to address internal control weaknesses.

ABVC BioPharma reports increased revenue for fiscal year 2024, but faces ongoing financial challenges and a restatement of prior year financials.

ABVC BioPharma has filed an amendment to its annual report on Form 10-K to include previously omitted exhibits related to insider trading policy and incentive compensation recovery.

ABVC BioPharma's 2023 annual report details a year of strategic shifts, pipeline advancements, and financial challenges, including a significant net loss and efforts to maintain Nasdaq listing compliance.

ABVC BioPharma, Inc. announces its 2026 Annual Meeting of Shareholders to vote on director re-elections, auditor ratification, and an increase in its equity incentive plan, while facing a 'going concern' warning.

ABVC BioPharma is holding its 2025 annual shareholder meeting to vote on key proposals including director re-election, auditor ratification, land purchase authorization, and an equity incentive plan amendment.

ABVC BioPharma updates its proxy statement to include shares from a recent private transaction with Lind and clarifies quorum requirements for its upcoming annual meeting.

ABVC BioPharma is seeking stockholder approval to issue shares related to convertible notes and warrants issued to Lind Global Fund II, LP, to comply with Nasdaq listing rules, as part of a financing transaction to address the company's cash needs.

ABVC BioPharma is registering for the resale of up to 1,000,000 shares of its common stock underlying a warrant held by a selling stockholder.

ABVC BioPharma files an amendment to its Form S-1 registration statement to include information from its 2023 Annual Report on Form 10-K, pertaining to the resale of up to 11,714,683 shares of common stock by selling stockholders.

ABVC BioPharma files an amendment to its registration statement related to the resale of up to 11,714,683 shares of common stock by selling stockholders.

ABVC BioPharma is registering for resale up to 11.7 million shares of its common stock, primarily related to convertible notes and warrants issued to Lind Global Fund II, LP, as part of ongoing financial transactions.

ABVC BioPharma is registering for the resale of over 10 million shares of its common stock by selling stockholders, as detailed in a recent S-1 filing.

ABVC Biopharma's Chairman and Chief Business Officer, Eugene Jiang, has significantly increased his voting control over the company's common stock, now holding 18.50% of outstanding shares through direct ownership and various voting agreements.

ABVC BioPharma, Inc. Chairman and Chief Business Officer Eugene Jiang has significantly increased his voting control over the company's common stock to 17.4% through direct holdings and new voting proxy agreements with investors.

Lind Global Fund II LP, along with its general partner and managing member, disclosed a 3.2% beneficial ownership stake in ABVC BioPharma, Inc. as of June 30, 2025.

Lind Global Fund II LP, along with its general partner Lind Global Partners II LLC and managing member Jeff Easton, has disclosed a passive beneficial ownership of 9.9% in ABVC BioPharma, Inc., totaling 1,325,000 shares.